Skip to main content

30-03-2020 | Rheumatology | News | Article

Secukinumab gets EU nod for nonradiographic axSpA

Claire Barnard

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended expanding the indication for the interleukin (IL)-17A inhibitor secukinumab to include nonradiographic axial spondyloarthritis (axSpA).

Previously approved for psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, secukinumab may now be given to adult patients with nonradiographic axSpA and objective signs of inflammation as evidenced by elevated C-reactive protein levels and/or magnetic resonance imaging.

Secukinumab is supplied as vials containing 150 mg powder for reconstitution and administration by subcutaneous injection.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage